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Many studies have shown that the acidity of solid tumors contributes to local invasion and metastasis. Oral pH
buffers can specifically neutralize the acidic pH of tumors and reduce the incidence of local invasion and
metastatic formation in multiple murine models. However, this effect is not universal as we have previously
observed that metastasis is not inhibited by buffers in some tumor models, regardless of buffer used. B16-F10
(murine melanoma), LL/2 (murine lung) and HCT116 (human colon) tumors are resistant to treatment with lysine
buffer therapy, whereas metastasis is potently inhibited by lysine buffers in MDA-MB-231 (human breast) and
PC3M (human prostate) tumors. In the current work, we confirmed that sensitive cells utilized a pH-dependent
mechanism for successful metastasis supported by a highly glycolytic phenotype that acidifies the local tumor
microenvironment resulting in morphological changes. In contrast, buffer-resistant cell lines exhibited a pH-
independent metastatic mechanism involving constitutive secretion of matrix degrading proteases without
elevated glycolysis. These results have identified two distinct mechanisms of experimental metastasis, one of
which is pH-dependent (buffer therapy sensitive cells) and one which is pH-independent (buffer therapy resistant
cells). Further characterization of these models has potential for therapeutic benefit.
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Progression to metastatic disease remains the highest mortality risk for
cancer patients, despite significant efforts to therapeutically target
metastatic lesions [1,2]. Microenvironmental acidosis in a primary
tumor increases cellular motility and invasiveness, leading to increased
metastasis [3–5]. During primary tumor development, cell metabo-
lism is often altered resulting in up-regulated glycolysis even in well-
oxygenated environments [2,6]. Aberrant glycolytic flux, the
“Warburg Effect”, results in intracellular lactate and proton pools,
both of which are shuttled into the tumor microenvironment by
monocarboxylate and proton transporters to maintain intracellular
pH (pHi) at physiologic levels [7,8]. One such transporter, carbonic
anhydrase-9 (CA-IX) is a negative prognostic indicator in many
cancers [9,10]. In addition to excessive H+ secretion, the chaotic
architecture of tumor vasculature results in a reduced capacity of
tumors to remove cellular waste. As a result, the extracellular pH
(pHe) of tumors is significantly more acidic (pH 6.5-6.9) than normal
tissue (pH 7.2-7.5) [11,12]. As acidosis is a common phenotype insolid tumors, we have developed a strategy to neutralize acidity using
orally ingested buffers [13]. We have shown previously that treatment
of mice with orally available buffers is efficacious in reducing
spontaneous and experimental metastasis by increasing pHe due to
higher buffering capacity of blood [14]. This is a targeted effect, as it
only brings into balance the pH of tissues that were previously out of
the physiological range [13]. Increased tumor pHe after treatment
with oral buffers has been confirmed through magnetic resonance
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6.4), 2-imidazole-1-yl-3-ethoxycarbonylpropionic acid (pKa = 6.9),
and free-base lysine (pKa = 10) have all been shown to be effective in
reducing metastases in vivo[14–16]. Reduction of metastasis is
dependent upon buffering, as reducing the buffering capacity of free-
base lysine by lowering the pH to pH 8.4 (below the second pKa)
rendered the therapy significantly less effective [17]. Treatment with
buffer therapy is non-toxic, as mice maintain their weight, blood pH,
renal function and immune cell distribution throughout the course of
treatment [14–16]. Notably, the efficacy of buffer therapy is not
universally observed. Metastases in two cell lines; MDA-MB-231,
human breast adenocarcinoma; and PC3M, prostate adenocarcino-
ma; are both inhibited by buffer therapy, while B16-F10 cells, murine
melanoma, and LL/2 cells, murine lung carcinoma, were resistant to
the same treatment [14–16]. Of the currently available buffers, lysine
is the most efficacious as it has the highest pKa of the three [13].
The success of buffer therapy suggests that, at least in sensitive cells,
there is a metastatic mechanism that has an acidic pH optimum.
Furthermore, proteases contribute to tissue remodeling during the
metastatic cascade, and overexpression of matrix metalloproteases
(MMPs) has been observed in a number of tumors and is a predictor
of progression to metastatic disease [18,19]. Another type of protease,
cysteine cathepsins, are lysosomal in origin but can be excreted into the
tumor microenvironment [20]. Acidity and proteases have been linked in
the “acid-mediated invasion” hypothesis which proposes that acidifica-
tion of the tumor microenvironment can be associated with
cathepsin release to trigger matrix remodeling [21]. Cell migration
through tissue can occur through different mechanisms, either as
single cells or in a collective fashion [22,23]. Cell migration
patterns have been further classified based on cellular morphology
of rounded and elongated cell types in 3D culture systems as well as
in-vivo tumor models [24]. Additionally, tumor acidity and
expression of proton pumps have been associated with increased
cellular migration and invasion in breast and melanoma cell lines
[25–27].
This study investigates the mechanisms of buffer therapy resistance.
The observation that buffering is not universally efficacious led us to
hypothesize that resistant and sensitive lines utilize different metastatic
mechanisms, one that is pH-independent and one that is pH-dependent.
Metabolic profiling confirms that buffer-sensitive lines have a much
more robust glycolytic phenotype, compared to resistant lines, and
that this is coupled to increased tumor acidification. In contrast,
resistant lines constitutively expressed proteases in a pH-indepen-
dent fashion, compared to sensitive lines whose protease activities
were low and pH-dependent. Acidic pHe results in morphological
changes in sensitive cells, while resistant cells were unaffected. We
propose that sensitive cells activate proteases and alter their
morphology by acidifying their microenvironment, which can be




Animals were housed according to Institutional Animal Care and Use
Committee protocol at the University of South Florida Vivarium within
Moffitt CancerCenter. Four- to six-week-old SCID-beige (Charles River)
or nu/nu mice (Harlan) were used in experimental metastasis models or
for fluorescent imaging of subcutaneous tumors, respectively.Cell Lines
PC-3M-Luc6 clone, B16-F10-G5 clone and LL/2-M38 clone
luciferase expressing cells were obtained from Xenogen Caliper.
MDA-MB-231 and HCT116 cells (American Type Culture Collec-
tion) stably expressing luciferase were generated using lentiviral
transduction. Cells were cultured in typical incubation conditions
(37°C and 5%CO2). Cell counts and diameters weremeasuredwith the
Countess Automated Cell Counter (Invitrogen).
Experimental Metastasis Model and Bioluminescent Imaging
Experimental metastasis models and bioluminescent imaging was
performed as described previously [16]. SCID-beige mice were pretreated
with 200 mmol/l lysine or tap water for 1 week before injection, and
continued throughout the study. 1 × 106 cells were injected intravenously
in 100 μl PBS. Mice were imaged immediately after injection by
bioluminescent imaging to confirm successful injections. Metastasis
formation is inferred from bioluminescent signal, which is reported as
mean log photons emitted/second ± SEM. MDA-MB-231 growth rate
doubling times (DT) were determined by fitting three parameter
Gompertz function [28,29]. Statistical significance using Log-DT as a
descriptor for the groups was determined using one-sided ANOVA test.
Metabolic Profile Analysis
Metabolic profiles were determined using the Seahorse Extracellular Flux
(XF-96) analyzer (Seahorse Bioscience Chicopee, MA) as described
previously [16]. Briefly, assay media was supplemented with 11 mmol/l
glucose, 0.5 mmol/l sodium pyruvate and 2 mmol/l glutamine for
mitochondrial stress tests and glucose-free media for glycolysis stress tests.
Cells were treated with 1 μmol/l oligomycin, carbonyl cyanide 4-
(Trifluoromethoxy) Phenylhydrazone, rotenone and antimycin during
mitochondrial stress test. Glycolysis stress test treatments include 11mmol/
l glucose, 1 μmol/l oligomycin and 100 mmol/l 2-deoxyglucose. ECAR
and oxygen consumption rate (OCR) values were standardized to
mg/protein and reported as the mean ± SD.
Electrode Measurement of Tumor pH
pH measurements were performed as described previously [15].
Briefly, a reference electrode was placed in a non-tumor site. A needle
microelectrode (optical density 0.8 mm with a beveled end) was inserted
into the center of the tumor andwas held in place until readings stabilized.
pH was measured at three locations and reported as mean ± SEM.
In Vivo Protease Activity Measurements
nu/nuMicewere providedwith either tapwater or 200mmol/l free base
lysine 7 days before inoculation (Sigma Aldrich St. Louis, MO). 1 × 106
LL/2 or PC3M cells were injected as bilateral subcutaneous flank injections
in PBS solution. Twenty-four hours before imaging, mice were injected
with activatable fluorescent probes, MMPsense680 and Prosense750EX
(Perkin Elmer Waltham, MA), intravenously. In vivo measurements were
obtained using the FMT2500 (Perkin Elmer) tomographic imaging
system. Fluorescent signal from each probe was quantified based on an
internal standard. Data were reported as mean ± SD.
Quantitative PCR (qPCR)
RNA was isolated from cell pellets using RNeasy Mini Kit
(Qiagen). qPCR reactions were carried out with iScript One-Step
RT-PCR kit with SYBR Green (Bio-Rad) using Applied Biosystems
StepOne PCR system (Applied Biosystems Grand Island, NY).
MMP-2 and MMP-9 primers were obtained from S. Chellepan
(Moffitt Cancer Center) (Supplemental Table 1). Data were analyzed
using ΔΔCt, with the gene of interest normalized to β-actin.
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Cells were pre-labeled with 10 μg/ml of DilC12(3) (BD Biosciences San
Jose, CA) before seeding cells in serum free media into the apical chambers
of the BD BioCoat™ Tumor Invasion System (BD Biosciences). Media
containing serum was used as a chemo-attractant in the basal chambers.
Fluorescence readings were obtained every 6 hours using a BioTek Synergy
HT plate reader (BioTek Instruments Winooski, VT).
Microscopy Studies
Cell migration assays were conducted using a 96-well plate Wound-
Maker™ (Essen BioScience Ann Arbor, MI) to create homogenous 700-
to 800-μmwounds. Images were recorded every 30 minutes and wound
properties, including % Relative Wound Density (%RWD, shown
below), were measured with IncuCyte Software (Essen BioScience).
%RWD tð Þ ¼ 100 w tð Þ−w 0ð Þ½ = c tð Þ–c 0ð Þ½ ;
where w tð Þ ¼ Density of wound region at time t;
and c tð Þ ¼ density of cell region at time t:
Migration videos were recorded with a JuLi microscope using a 10×
objective lens (NanoEnTek) and generated with ImageJ software. Cell
morphology studies were performed as previously described [24].
Confocal images were obtained with an Olympus FV1000
MPE multiphoton laser scanning microscope through a 60× LUM
Plan FI/IR 0.9N.A. water immersion lens (Olympus). 405 diode and
Red HeNe lasers were used to excite the samples. Images were prepared
using the FV10-ASW Version 03.00.01.15 software (Olympus).
Data Analysis
Data were analyzed using GraphPad Prism v6.02 (GraphPad Software,
Inc. GraphPad Software, Inc. (La Jolla, CA) and Matlab (MathWorks, Inc.
Natick,MA). Statistics were performedusing an unpaired 2-tailed Student’s t
test with Welch’s correction. Data are reported as mean ±SD or ±SEM.Results
We have previously shown that experimental metastasis of PC3M
cells was inhibited by 200 mmol/l lysine (pH = 10.1) (Supplemental
Figure 1, A–C) [16,17]. Importantly, neutralized lysine (pH = 8.4)
was much less effective in preventing metastases than lysine (pH =
10.1), showing the effect was due to buffering capacity [17]. In
the current study, we sought to identify additional lysine-sensitive
and -resistant cell lines using experimental metastasis models. Mice
were pretreated with 200 mmol/l lysine or tap water for 1 week before
intravenous injection of Firefly-luciferase expressing cells. Consistent with
previous work, B16-F10 metastasis were unaffected by lysine treatment
(Figure 1A)[14]. LL/2 cells were similarly unresponsive to lysine
treatment, showing no difference in metastasis formation or survival
benefit with treatment (Figure 1B and Supplementary Figure S1D).
MDA-MB-231 cells experienced significantly lower metastatic burden
after therapy (P b .05), which translated into a significant survival
benefit (P b .05) (Figure 1D). HCT116 cells had not previously been
tested using an experimental metastasis model, but had shown a
reduction in local invasion in a window-chamber model when treated
with 200 mmol/l bicarbonate [21]. In contrast to those results,
treatment of mice with lysine had no effect on HCT116 metastatic
formation or survival (Figure 1C and Supplementary Figure S1E). From
this point on, cells will be identified as resistant or sensitive to lysine
therapy with subscripts (R = resistant; S = sensitive).
We subsequently performed in vitro studies to identify potential
mechanisms of resistance. Profiling cell lines in vitro confirmed thatcultured cells resemble cells grown in vivo, giving us confidence that
mechanisms identified in vitro translate in vivo. For example, growth
rates of resistant cells (B16-F10R, LL/2R and HCT116R) were
significantly higher compared to sensitive cells (PC3MS and MDA-
MB-231S) (P b .001) (Figure 1E). The in vitro growth curves closely
followed in vivo growth rates, with B16-F10R and LL/2R expanding
significantly faster than PC3MS and MDA-MB-231S (P b .0001)
(compare Figure 1, A, B, D and S1C with Figure 1E), and HCT116R
growing at an intermediate rate (Figure 1, C and E). Cell size was
measured to estimate their size in circulation, showing resistant cells
were significantly smaller in suspension than were the sensitive cells
(P b .05) (Figure 1F), which may allow for more rapid extravasation
during metastasis.
Buffer therapy selectively increases the pHe of tumors; hence, we
sought to determine the effect of pH on invasion in vitro[14,15].
Using fluorescently labeled cells in a Boyden chamber system, cell
invasion was quantitatively measured over 48 hours in either pH 6.8
or pH 7.4 media. Uptake of fluorescent dye had no adverse effect on
cell proliferation (data not shown). Invasion rates were measured for
each cell line and analyzed to determine the differential rate of
invasion between each pH condition, in order to self-normalize for
differences in uptake of the fluorescent dye across cell lines. Resistant
cells, B16-F10R, LL/2R, and HCT116R showed no significant change
in their rates of invasion between pH 6.8 and pH 7.4 (Figure 2).
MDA-MB-231S cells, however, had a significantly increased rate of
invasion at pH 6.8, relative to pH 7.4, when compared to B16-F10R
(P b .05), LL/2R (P b .05), and HCT116R (P b .005) (Figure 2).
While not statistically significant, PC3MS cells followed the same
trend as MDA-MB-231S cells of having an increased rate of invasion
at pH 6.8 relative to pH 7.4 (Figure 2). As growth rates are suppressed
under these acute acidic conditions for each cell line (data not shown),
we conclude that the increased invasion rate in sensitive cell lines is a
real phenomenon and not the result of growth rate differences.
Together, these data suggest that resistant and sensitive cells utilize
different invasive mechanisms, pH-independent, and pH-dependent
mechanisms, respectively.
The Warburg Effect is a common phenomenon in solid tumors
that contributes to acidification of the tumor microenvironment.
Originally, we hypothesized resistant lines would produce acid at a
higher rate, implying that increasing the buffer load could overcome
buffer resistance. To test this, we examined the effect of 400 mmol/l
bicarbonate on experimental B16-F10R metastasis formation and
observed no effect (data not shown), suggesting resistant cells were not
merely producing acid at a higher rate. This was verified by metabolic
profiling of resistant and sensitive cells using a Seahorse XF® analyzer
which measures real-time H+ production and oxygen consumption rate
over amonolayer of cells in a transientmicrochamber.Metabolic profiling
assays were performed in parallel and normalized to either cell number or
protein concentration, to confirm that normalized results were not an
artifact of cell size differences (data not shown). To determine glycolytic
activity, a “glycolytic stress test”was performed,which includesmeasuring
extracellular acidification rates (ECAR) after sequential addition of
glucose to measure basal glycolysis, a mitochondrial poison (oligomycin)
to estimate total glycolytic capacity, and 2-deoxyglucose to measure non-
glycolytic ECAR. Interestingly, sensitive cells had significantly higher
basal glycolytic rates, compared to resistant cells (P b .0001) (Figure 3A).
Glycolytic reserve is calculated bymeasuring the difference in themaximal
glycolytic capacity, after treatment with oligomycin, and basal glycolysis.
Possibly as a consequence of their high basal rates, the sensitive cells
Figure 1. Effect of lysine on metastasis and survival. Efficacy of lysine was determined by pre-treating SCID-beige mice for a week before
tail vein injection of cells stably expressing Firefly-luciferase in an experimental metastasis model. Treatment with 200 mmol/l lysine was
administered continuously throughout the experiment. Metastasis formation was measured by bioluminescent imaging, reported as log
photons per second ± SEM, and representative bioluminescent images of one mouse per cohort for each experiment are shown at the
times indicated. Bioluminescent imaging of B16-F10 metastasis (Tap n = 10, Lysine n = 10)(A), LL/2 metastasis (Tap n = 10, Lysine n =
10) (B), and HCT116 metastasis (Tap n = 8, Lysine n = 10) (C) shows buffer therapy is ineffective. (D) Bioluminescent imaging of MDA-
MB-231 metastasis shows buffer therapy is effective in reducing metastatic formation (upper panel) leading to a significant increase in
survival (bottom panel) (Tap n= 5, Lysine n= 8). (E) Average cell growth curves measured over 72 hours indicates significant growth rate
differences between resistant and sensitive cells and correlate with in vivo tumor growth rates. Data shown as mean cell number ± SD.
(F) Cell diameter measurements of single cells in suspension show resistant cells are significantly smaller than sensitive cells.
Data shown as mean cell diameter (μm) ± SD. Cells will be identified as resistant or sensitive to treatment with subscripts (R = Resistant;
S = Sensitive). *P b .05; ***P b .001; ****P b .0001.
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Figure 2. Effect of pHe on invasion rates of resistant and sensitive
cells. In vitro invasion assay using a Boyden chamber coated with
Matrigel. Fluorescently labeled cells were measured every 6 hours
for 48 hours for invasion through Matrigel layer. Data shown is the
result of two biologic experiments (n = 6/sample) normalized to
wells lacking serum attractant (n= 2/sample). Data is presented as
the mean difference in the rate of invasion of cells cultured in pH
6.8 and cells cultured in pH 7.4 ± SD. The rate of invasion of
sensitive cells increases in pH 6.8 compared to resistant lines.
*P b .05; **P b .005. R, resistant; S, sensitive.
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resistant cells (P b .0001), suggesting that they are near maximum
glycolytic capacity in their basal metabolic state (Figure 3B).
The rate of decrease in O2 can be converted to an OCR. The
“mitochondrial stress test” initially determines basal respiration. We
observed that resistant cells had significantly higher basal OCR compared
to sensitive cells (P b .05) (Figure 3C). We suspect that the higher basal
OCR in resistant cells is most likely related to the energy demands of a
higher proliferation rate (Figure 1E). Treatment with an inhibitor of the
F0 subunit of mitochondrial adenosine triphosphate (ATP) synthase,
oligomycin, providedOCR attributed directly to ATP production. These
data showed that buffer therapy resistant cells had significantly higher
OCR that attributed to ATP production (P b .0001) (Figure 3D).
These mitochondrial stress test data suggest that resistant cells rely on
mitochondrial oxidative metabolism (OXPHOS) for their energy needs.
Metabolic analysis of OXPHOS and glycolytic pathways in resistant
and sensitive cells showed distinct metabolic profiles. This can be
directly shown by expressing data as basal OCR/ECAR ratios, which are
self-normalized and showed that sensitive cells were significantly
(P b 0.0001) more glycolytic than resistant cells (Figure 3E). These
differences in metabolic profiles were related to the ability of
buffer therapy to inhibit metastasis (Figure 1, A–D, Supplemental
Figure 1, A–C), and correlate with distinct phenotypic differences in
their in vivo and in vitro proliferation rates (Figure 1E), and size
(Figure 1F). pHe measurements of PC3MS and B16-F10R tumors
support the metabolic evidence presented, with PC3MS tumors being
more acidic than B16-F10R tumors (Figure 3F). Previous studies, using
MRS imaging with the pH indicator 3-aminopropylphosphonate (3-
APP) and fluorescent ratio imaging with SNARF-1, have shown that
MDA-MB-231 tumors are similarly acidic and can bemanipulatedwith
buffer therapy to increase the tumor pH [14]. We have previously
observed sensitivity of HCT116-GFP cells to bicarbonate in window-chamber studies [21], but observed clear resistance of HCT-116R-Luc
cells in our current studies. Interestingly, HCT116-GFP cells had a
different metabolic profile than the HCT116R-Luc cells used in the
in vivo experimental metastasis model herein, suggesting the presence
of two phenotypically distinct populations of these cells, supported by
differences in their OCR/ECAR ratios (P b .0001) (Supplementary
Figure 3). Importantly, DNA fingerprinting confirmed that both lines
used were HCT116 colorectal cells (data not shown). Notably, the
glycolytic HCT-116-GFP cells were inhibited by buffer therapy [21];
whereas the oxidative HCT-116-luc cells were not (Figure 1C).
Invasion kinetics and metabolic profiling suggest that resistant cells
invade via a mechanism that is pH-independent. Proteases have been
identified as key enzymes involved in the metastatic cascade. Prior
data have shown that low pH significantly stimulated the release of
active cathepsin-B from buffer-sensitive MDA-MB-231 cells in 2-D
and 3-D culture [14,30]. Hence, we hypothesize that resistant cells
may release active proteases in a constitutive, pH-independent
fashion. To investigate this, we imaged mice bearing tumors using
fluorescent indicators that are activated by protease activity. ProSense
750EX and MMPsense 680 fluoresce upon cleavage by Cathepsins B,
L, S and Plasmin (ProSense 750EX) or MMPs-2, -3, -9 and -13
(MMPsense 680). Using a tomographic near-IR fluorescence imaging
system, FMT2500, activated probes were imaged 24 hours post-
probe injection followed by fluorescent signal integration over the
tumor region of interest (ROI). B16-F10R tumors were not used due
to high melanin levels that quench fluorescence. Thus, we measured
the in vivo protease activity of the most resistant (LL/2R) and the
most sensitive (PC3MS) cell lines (Figure 1B and Supplemental
Figure S1, A–C). Quantification of activated ProSense 750EX in LL/2R
tumors showed significantly higher cysteine cathepsin
activity compared to PC3MS under control conditions (P b .0001)
(Figure 4, A,C). Although treatment reduced ProSense 750EX activation
in LL/2R tumors (P b .05), activity still remained significantly higher than
PC3MS cells under either pH condition (Figure 4,A,C) [20]. Conversely,
MMPsense 680 was visibly activated in both LL/2R and PC3MS tumors
in control mice (Figure 4,B,D). Buffer treatment increasedMMP activity
in LL/2R tumors (Pb 0.05), and reducedMMP activity 2-fold in PC3MS
tumors, but was not statistically significant (Figure 4,B,D). Resistant LL/
2R tumors had higher intrinsic cathepsin activity than did PC3MS tumors
and elevated MMP activity after buffer therapy. Therefore, we can
conclude that resistant lesions have more protease activity compared to
sensitive lesions, which may be contributing to buffer therapy
resistance.
To confirm in vivo protease activity results, cell cultures exposed
to media at pH 7.4 or pH 6.8 were analyzed for MMP-2, -3, -9, and
-13 (MMPs that activate MMPsense 680) mRNA expression. We
chose to focus on MMP expression due to the significant increase of
MMP activity observed upon treatment with lysine in LL/2R tumors
(Figure 4, B,D). Both LL/2R and PC3MS cells exhibited an increased
expression of MMP-3 and -13 at pH 6.8 (Figure 5A). To further
compare differences, transcript expression in LL/2R cells was normalized
to PC3MS cultures. LL/2R cells have higher MMP expression compared
to PC3MS cells for each of the transcripts analyzed, with the exception of
MMP-9 (Figure 5B). Importantly, there were no differences in the fold
change of each transcript relative to PC3MS when exposed to acidic or
physiological conditions, showing that higher proteolytic expression of
resistant cells was pH-independent. MMP transcript analysis confirms
our hypothesis that buffer therapy resistant lines are constitutively
proteolytic in vitro (Figure 5) as well as in vivo (Figure 4).
Figure 3. Metabolic profile analysis of resistant and sensitive cells and tumor pH. In vitro oxygen consumption rate (OCR) and
extracellular acidification rate (ECAR) of resistant and sensitive cells, measured using Seahorse XF-96 Instrument. Metabolic data are
presented asmean± SD. (A) ECARmeasurements in response to 5.55mmol/l glucose stimulation indicate basal glycolytic activity of
cells. Sensitive cells are significantly more glycolytic than resistant cells. (B) The increase in ECAR of cells in response to treatment
with 1 μmol/l oligomycin minus basal glycolytic activity indicates the glycolytic reserve of cells. Sensitive cells have significantly
reduced glycolytic reserve compared resistant cells.(C) Basal OCR measurements show significantly higher oxidative
phosphorylation flux in resistant cells compared to sensitive cells. (D) OCR contributing to production of ATP during oxidative
phosphorylation is measured by the difference of basal OCR and the OCR of cells after treatment with 1 μmol/l oligomycin, a
mitochondrial ATP synthase inhibitor. The amount of OCR contributing to the production of ATP by oxidative phosphorylation is
significantly higher in resistant cells compared to sensitive cells. (E) The OCR/ECAR ratio of cells during basal metabolism indicates
that sensitive cells are significantly more glycolytic than resistant cells. (F) Intratumoral pH measurements of subcutaneous tumors
using pH electrodes shows that increased glycolytic activity of sensitive cells, PC3MS, contributes to a more acidic tumor
microenvironment than resistant tumors, B16-F10R. pH data are presented asmean of independentmeasurements (B16-F10Rn=10;
PC3MSn = 5) ± SEM. *P b .05; ****P b .0001. R, resistant; S, sensitive.
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Figure 4. Resistant tumors have increased in-vivo protease activity. Mice bearing LL/2R (Tap n = 7, Lysine n = 8) and PC3MS (Tap n = 7,
Lysine n = 5) tumors were injected with activatable probes, ProSense 750EX and MMPsense 680, which report Cathepsin and MMP
activity, respectively. Representative images of fluorescent tomographic imaging showing cathepsin activity through ProSense 750EX
signal (A) through MMPsense 680 (B) in LL/2R and PC3MS tumors in mice receiving either tap water or lysine buffer. (C) Quantitation of
ProSense 750EX activated signal in tumors, normalized to tumor size. (D) Quantitation of MMPsense 680 activated signal in tumors,
normalized to tumor size. Data are presented as mean nanomolar concentration ± SD. *P b .05; **P b .01; ****P b .0001. R, resistant; S,
sensitive.
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migration and invasion during metastasis [22]. To understand
migratory differences between LL/2R and PC3MS, we monitored cell
motility in a wound healing assay. Cell migration was observed by
imaging cells for 18 hours after wound formation. Percent relative
wound density was calculated by measuring the density of cells that
migrated into the original wound. LL/2R cells were significantly more
migratory than PC3MS cells cultured in physiologic pH (p b 0.0001)
(Figure 6, A–B). Interestingly, exposure to low pH had differential
effects on cell migration for each of the cell lines. LL/2R migration
across the wound was significantly retarded under acidic conditions
(P b .01), while PC3MS cell migration was significantly accelerated
under acidic conditions (P b .0001) (Figure 6, A–B). Additionally,
sensitive and resistant cells exhibited different modes of migration.
PC3MS cells moved across the wound as a mass following leading cells,
suggestive of a collective cell migration phenotype, while LL/2R cellsmoved as single cells, which is characteristic of single-cell or multicellular
streaming invasive phenotypes (Supplemental Video).While studying the
movement of cells in a 2D culture environment is useful, 3D cultures
more closely resemble physiological obstacles encountered during
metastasis. Using phalloidin staining, we studied the morphology of
LL/2R and PC3MS cells in a thick (500–1000 μm) layer of Matrigel®
under physiological or acidic conditions. In a 3D matrix LL/2R and
PC3MS cells have distinctly different cellular morphologies. PC3MS cells
have an elongated phenotype with multiple protrusions into the local
matrix (Figure 7 and Supplemental Figure 4). In response to acidic
conditions, PC3MS cells maintained an elongated phenotype although
completely void of the protrusions that were observed under physiological
conditions, which may allow for greater invasive potential. In contrast,
LL/2R cells had a rounded morphology that, consistent with the
phenotypes we characterized above, remain unchanged from physiologic
to acidic pH (Figure 7 and Supplemental Figure 4).
Figure 5. Elevated MMP expression in resistant cells. Quantitation
of MMP expression in sensitive and resistant cells grown in
physiological or acidic pH media for 24 hours. Transcripts were
normalized to β-actin expression before analysis. (A) Ratio of
expression of MMP-2, -3, -9 and -13 in LL/2R and PC3MS cultured in
acidicmedia relative to cells cultured in physiologicalmedia. (B) Ratio
of expression of MMP-2, -3, -9, and -13 in LL/2R cells relative to
expression in PC3MS cells cultured in acidic and physiologicalmedia.
Data are the average of three independent experiments and is
reported as mean ± SD. *P b .05. R, resistant; S, sensitive.
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In our previous studies, we demonstrated that an acidic microenviron-
ment is critical for carcinogenesis and tumor invasion. Furthermore, we
have found that systemic buffers reduce intra- and peri-tumoral acidity,
inhibit carcinogenesis in transgenic mice, and inhibit metastatic growth
in a wide range of cell lines in-vivo[14,21,31]. However, as with most
therapeutic regimens, efficacy of buffer therapy was not universally
observed. The current work focused on identifying molecular and
metabolic phenotypes of resistant cells, with an expectation that such
data could identify additional biomarkers to stratify tumors for their
response to buffer therapy. Using a panel of cells representing different
cancers, we have characterized two responsive cell lines, PC3MS and
MDA-MB-231S, and three resistant cell lines, B16-F10R, and LL/2R,
HCT116R. In addition to faster growth rates in vivo and in vitro,
resistant cells were significantly smaller in diameter than sensitive cells,
whichmay allow increased access to invade the extracellular space, either
through more efficient extravasation or secondary site colonization.
Faster growth and smaller size may be enough to render resistant cells
too aggressive for buffer therapy to be effective.
Further exploration, however, has revealed a number of other
important molecular and metabolic parameters that could contribute
to resistance. Kinetic invasion assays suggest that there are distinct
mechanisms used for invasion by these two groups. Sensitive lineinvasion is pH-dependent, allowing buffer therapy to intercept
metastasis by neutralizing acidity in vivo. Resistant cell line invasion,
on the other hand, is pH-independent, bypassing the need for acidosis
to metastasize.
Metabolic alterations contribute to acidification of tumor microen-
vironments. Metabolic profiling showed that sensitive cells were
unequivocally more glycolytic than the resistant cells. Cells with
elevated glycolysis produce more acidic tumors. Previously, we have
confirmed that buffer therapy is an effective method of increasing the
pHe of tumors, which diminishes the ability of sensitive, but not
resistant cells, to invade locally and metastasize [14–16].While resistant
tumors were less acidic than highly glycolytic sensitive tumors, they
were nonetheless more acidic relative to normal tissues, likely due to
poor perfusion. Neutralizing the tumor acidity in these tumors had less
of an effect on their metastatic potential because they have upregulated
mechanisms to bypass the need for acid-stimulated invasion.
Expression, release, and enzymatic activity of proteases are regulated
by acidosis. While sensitive cells, PC3MS, have measureable expression
of MMPs, resistant cells, LL/2R, have consistently higher expression of
MMPs regardless of pH. Expression of MMPs correlated with protease
activity in vivo. Interestingly, LL/2R tumors had a significant increase in
MMP activity in response to treatment, suggesting buffer therapy could
exacerbate the metastatic burden, although increases in metastatic
formation in mice receiving buffer therapy was not observed. Protease
activation in resistant tumors is not adversely affected by buffer therapy,
and allows resistant lines to circumvent inhibition of metastasis by
buffer therapy. Similar results were observed in a parallel study [30], in
which acidic pHe increased pericellular active cysteine cathepsins in vitro,
which was reduced after buffer therapy treatment in vivo. Furthermore,
resistant and sensitive cells exhibited distinct morphological differences in
3D culture systems. Interestingly, acidic conditions resulted in the loss of
protrusions in 3D culture of PC3MS, which may contribute to their
increased invasiveness in acidosis. Resistant and sensitive cells consistently
had differential responses to changes in extracelluar pH, regardless
of the inclusion or absence of Matrigel matrix (migration, invasion
and morphology studies), suggesting that the changes observed
were due to pH alterations, rather than cell signaling pathways such
as integrin signaling.
Although buffer therapy is not universally effective in reducing
metastases, it does have potential advantages over targeted cytotoxic
chemotherapies that are in current clinical practice. Tumors
are heterogeneous, containing genetically distinct regional sub-
populations that originate over a lifetime of tumor growth [32–34].
Intrinsic or acquired resistance to chemotherapy is a major obstacle of
targeted therapies clinically, and will continue to remain so for the
foreseeable future [35]. In contrast, treatment of solid tumors with
buffer therapy targets tumor acidity, a common phenotypic conse-
quence of tumor somatic evolution [36,37]. In addition to enhancing
local invasion and metastatic potential, tumor acidosis contributes to
drug resistance through ion-trapping of weakly basic chemotherapeu-
tics, preventing active drug from reaching therapeutic doses within cells
[38–40]. Therefore, buffer therapy may also be useful as an adjuvant to
traditional chemotherapies. Notably, a clinical trial of buffer therapy in
cancer patients has recently been initiated (NCT01846429).
In the current studies, buffer therapy was initiated before
inoculation to prevent progression to metastatic disease. Previous
studies show buffer therapy has little effect on reducing primary
tumor growth, but significantly reduces spontaneous metastasis
formation [14]. Similarly, in a transgenic prostate cancer model,
Figure 6. Migratory patterns of LL/2R and PC3MS cells; 700- to 800-μm wounds were created in confluent cell cultures exposed to
physiologic or acidic media 24 hours before wound formation, and during the duration of the experiment. Samples were imaged in
30-minute intervals for 18 hours. (A) Representative microscopy images of LL/2R (upper panel) and PC3MS (lower panel) showmovement
across a wound at 0 and 18 hours in pH 7.4 or pH 6.8 media. Scale bars represent 300 μm. (B) Percent relative wound density was
determined by measuring the density of cells within the original wound site at each of the time points imaged. Data are shown as the
mean ± SEM and are representative of three independent experiments. **P b .01; ****P b .0001; R, resistant; S, sensitive.
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when therapy was initiated immediately after weaning (4 weeks of
age) [31]. Interestingly, if therapy was initiated later (10 weeks of age)
development of prostate cancer was delayed, but was not inhibited,
while progression to metastatic disease was still prevented with
treatment. Our data shows that buffer therapy is an effective method
of halting tumor progression and metastasis formation, but also
indicates that the timing of therapy initiation is instrumental for
maximal efficacy. Future studies on optimization of buffer therapy
delivery and treatment schedules are necessary to harness the full
potential of buffer therapy clinically.
Identifying distinct metastatic mechanisms of sensitive and
resistant tumors allows for the identification of predictive biomarkers
of buffer therapy response. FDG-PET screening may be an idealmethod of screening patients to assess their glycolytic phenotype to
predict response to buffer therapy. Clinically, FDG-PET imaging is
used to diagnose up to 90% of primary tumors, indicating that the
vast majority of patients have glycolytic tumors that may benefit from
treatment with buffer therapy [41]. Further screening of additional
cell lines for responsiveness to buffer therapy will help solidify
potential biomarkers or alternative treatments for resistant tumors. A
current limitation of our research was the use of five cell lines
originating from different cancers. Deeper analysis into panels of cell
lines originating from the same primary organ site will surely provide
more insight and will need to be studied in the future. Such
observations are commencing with the identification of two
populations of HCT116 cells that have distinctly different metabolic
and invasive behaviors.
Figure 7. Morphologies in a 3D matrix in vitro. LL/2R and PC3MS cells were seeded onto a thick (500-1000 μm) layer of polymerized
Matrigel and invaded into the matrix over a period of 72 hours in pH 6.8 or pH 7.4 media. Single cells were imaged using confocal
microscopy for morphological studies. Representative images of PC3MS cells (upper panels) and LL/2R cells (lower panels) show a 3D
reconstruction of at least 20 slices. Phalloidin (F-actin) is shown in red, Hoechst nuclear stain is shown in blue. Scale bars represent
10 μm. , resistant; , sensitive.
Neoplasia Vol. 16, No. 4, 2014 Mechanisms of buffer therapy resistance Bailey et al. 363Acknowledgments
Grant Support: This study was supported by grants U54 CA143970
(to R.A. Gatenby and R.J. Gillies); R01 CA 077575 (to R.J. Gillies
and R.A. Gatenby); and 1S10RR031726-01 (to D.L. Morse).
Conflicts of Interest: We have a Sponsored Research Agreement
with Seahorse Biosciences to develop methods for metabolic profiles of
biopsy tissues. This is relevant to the current publication, as a related
Seahorse instrument has been used tometabolically profile cells. The SRA
is limited to support for an assistant lab member, and related supplies.
References
[1] Chambers AF, Groom AC, and MacDonald IC (2002). Dissemination and
growth of cancer cells in metastatic sites. Nat Rev Cancer 2, 563–572.
[2] Hanahan D and Weinberg RA (2011). Hallmarks of cancer: the next generation.
Cell 144, 646–674.
[3] Moellering RE, Black KC, Krishnamurty C, Baggett BK, Stafford P, Rain M,
Gatenby RA, and Gillies RJ (2008). Acid treatment of melanoma cells selects for
invasive phenotypes. Clin Exp Metastasis 25, 411–425.
[4] Rofstad EK (2000). Microenvironment-induced cancer metastasis. Int J Radiat
Biol 76, 589–605.
[5] Rofstad EK, Mathiesen B, Kindem K, and Galappathi K (2006). Acidic
extracellular pH promotes experimental metastasis of human melanoma cells in
athymic nude mice. Cancer Res 66, 6699–6707.
R S[6] Warburg O, Wind F, and Negelein E (1927). The metabolism of tumors in the
body. J Gen Physiol 8, 519–530.
[7] Pinheiro C, Longatto-Filho A, Ferreira L, Pereira SM, Etlinger D, Moreira MA,
Jube LF, Queiroz GS, Schmitt F, and Baltazar F (2008). Increasing expression of
monocarboxylate transporters 1 and 4 along progression to invasive cervical
carcinoma. Int J Gynecol Pathol 27, 568–574.
[8] Pinheiro C, Longatto-Filho A, Scapulatempo C, Ferreira L, Martins S, Pellerin L,
Rodrigues M, Alves VA, Schmitt F, and Baltazar F (2008). Increased expression
of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows
Arch 452, 139–146.
[9] Ord JJ, Agrawal S, Thamboo TP, Roberts I, Campo L, Turley H, Han C,
Fawcett DW, Kulkarni RP, and Cranston D, et al (2007). An investigation into
the prognostic significance of necrosis and hypoxia in high grade and invasive
bladder cancer. J Urol 178, 677–682.
[10] Hussain SA, Ganesan R, Reynolds G, Gross L, Stevens A, Pastorek J,
Murray PG, Perunovic B, Anwar MS, and Billingham L, et al (2007).
Hypoxia-regulated carbonic anhydrase IX expression is associated with
poor survival in patients with invasive breast cancer. Br J Cancer 96,
104–109.
[11] Griffiths JR (1991). Are cancer cells acidic? Br J Cancer 64, 425–427.
[12] Wike-Hooley JL, Haveman J, and Reinhold HS (1984). The relevance of
tumour pH to the treatment of malignant disease. Radiother Oncol 2,
343–366.
[13] Silva AS, Yunes JA, Gillies RJ, and Gatenby RA (2009). The potential role of
systemic buffers in reducing intratumoral extracellular pH and acid-mediated
invasion. Cancer Res 69, 2677–2684.
364 Mechanisms of buffer therapy resistance Bailey et al. Neoplasia Vol. 16, No. 4, 2014[14] Robey IF, Baggett BK, KirkpatrickND, RoeDJ,Dosescu J, Sloane BF, HashimAI,
Morse DL, Raghunand N, and Gatenby RA, et al (2009). Bicarbonate increases
tumor pH and inhibits spontaneous metastases. Cancer Res 69, 2260–2268.
[15] Ibrahim Hashim A, Cornnell HH, Coelho Ribeiro Mde L, Abrahams D,
Cunningham J, Lloyd M, Martinez GV, Gatenby RA, and Gillies RJ (2011).
Reduction of metastasis using a non-volatile buffer. Clin Exp Metastasis 28, 841–849.
[16] Ibrahim Hashim A, Wojtkowiak JW, de Lourdes Coelho Ribeiro M, Estrella V,
Bailey KM, Cornnell HH, Gatenbyl RA, and Gillies RJ, et al (2011). Free base
lysine increases survival and reduces metastasis in prostate cancer model. J Cancer
Sci Ther S1.
[17] RibeiroMdLCSA, BaileyKM,KumarNB, Sellers TA,GatenbyRA, Ibrahim-Hashim
A, and Gillies RJ (2012). Buffer therapy for cancer. J Nutr Food Sci S2.
[18] Kessenbrock K, Plaks V, and Werb Z (2010). Matrix metalloproteinases:
regulators of the tumor microenvironment. Cell 141, 52–67.
[19] Deryugina EI and Quigley JP (2006). Matrix metalloproteinases and tumor
metastasis. Cancer Metastasis Rev 25, 9–34.
[20] Turk V, Stoka V, Vasiljeva O, Renko M, Sun T, Turk B, and Turk D (2012).
Cysteine cathepsins: from structure, function and regulation to new frontiers.
Biochim Biophys Acta 1824, 68–88.
[21] Estrella V, Chen T, Lloyd M, Wojtkowiak J, Cornnell HH, Ibrahim-Hashim A,
Bailey K, Balagurunathan Y, Rothberg JM, and Sloane BF, et al (2013). Acidity
generated by the tumor microenvironment drives local invasion. Cancer Res 73,
1524–1535.
[22] Friedl P, Locker J, Sahai E, and Segall JE (2012). Classifying collective cancer cell
invasion. Nat Cell Biol 14, 777–783.
[23] Friedl P and Alexander S (2011). Cancer invasion and the microenvironment:
plasticity and reciprocity. Cell 147, 992–1009.
[24] Sahai E and Marshall CJ (2003). Differing modes of tumour cell invasion have
distinct requirements for Rho/ROCK signalling and extracellular proteolysis.Nat
Cell Biol 5, 711–719.
[25] Reshkin SJ, Bellizzi A, Albarani V, Guerra L, Tommasino M, Paradiso A, and
Casavola V (2000). Phosphoinositide 3-kinase is involved in the tumor-specific
activation of human breast cancer cell Na(+)/H(+) exchange, motility, and
invasion induced by serum deprivation. J Biol Chem 275, 5361–5369.
[26] Stock C, Gassner B, Hauck CR, Arnold H, Mally S, Eble JA, Dieterich P, and
Schwab A (2005). Migration of human melanoma cells depends on extracellular
pH and Na+/H+ exchange. J Physiol 567, 225–238.
[27] Denker SP and Barber DL (2002). Cell migration requires both ion translocation and
cytoskeletal anchoring by the Na-H exchanger NHE1. J Cell Biol 159, 1087–1096.[28] Laird AK (1964). Dynamics of tumor growth. Br J Cancer 13, 490–502.
[29] Mehrara E, Forssell-Aronsson E, Johanson V, Kolby L, Hultborn R, and
Bernhardt P (2013). A new method to estimate parameters of the growth model
for metastatic tumours. Theor Biol Med Model 10, 31.
[30] Rothberg JM, Bailey KM, Wojtkowiak JW, Bennun Y, Boygo MS, Weber E,
Moin K, Blum G, Mattingly RR, and Gillies RJ, et al (2013). Acidic extracellular
ph increases contribution of cysteine cathepsins, including cathepsin B, to breast
carcinoma-associated proteolysis. Neoplasia 15, 1125–1137.
[31] Ibrahim-Hashim A, Cornnell HH, Abrahams D, Lloyd M, Bui M, Gillies RJ,
and Gatenby RA (2012). Systemic buffers inhibit carcinogenesis in TRAMP
mice. J Urol 188, 624–631.
[32] Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E,
Martinez P, Matthews N, Stewart A, and Tarpey P, et al (2012). Intratumor
heterogeneity and branched evolution revealed by multiregion sequencing.
N Engl J Med 366, 883–892.
[33] Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM,
Barber T, and Ptak J, et al (2007). The genomic landscapes of human breast and
colorectal cancers. Science 318, 1108–1113.
[34] Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH,
Eshleman JR, and NowakMA, et al (2010). Distant metastasis occurs late during
the genetic evolution of pancreatic cancer. Nature 467, 1114–1117.
[35] Shaw AT and Engelman JA (2013). ALK in lung cancer: past, present, and
future. J Clin Oncol 31, 1105–1111.
[36] Gatenby RA and Gillies RJ (2004). Why do cancers have high aerobic glycolysis?
Nat Rev Cancer 4, 891–899.
[37] Gatenby RA and Gillies RJ (2008). A microenvironmental model of
carcinogenesis. Nat Rev Cancer 8, 56–61.
[38] Jahde E, Glusenkamp KH, and Rajewsky MF (1990). Protection of
cultured malignant cells from mitoxantrone cytotoxicity by low extracel-
lular pH: a possible mechanism for chemoresistance in vivo. Eur J Cancer
26, 101–106.
[39] Raghunand N, Mahoney B, van Sluis R, Baggett B, and Gillies RJ (2001). Acute
metabolic alkalosis enhances response of C3H mouse mammary tumors to the
weak base mitoxantrone. Neoplasia 3, 227–235.
[40] Wojtkowiak JW, Verduzco D, Schramm KJ, and Gillies RJ (2011). Drug
resistance and cellular adaptation to tumor acidic pH microenvironment. Mol
Pharm 8, 2032–2038.
[41] Gambhir SS (2002). Molecular imaging of cancer with positron emission
tomography. Nat Rev Cancer 2, 683–693.
Supplemental Figure 1.
Sensitivity of PC3MS to treatment with lysine buffer therapy. (A–C) Figure reprinted from [16]. (A) Representative bioluminescent images
of PC3MS metastasis in SCID mice. (B) Ex vivo bioluminescent imaging of PC3MS metastasis. (C) Graphic representation of
bioluminescent imaging of PC3MS metastasis. Data is reported as log photons/sec ± SEM. Kaplan Meier curves showing survival of
experimental metastasis models of LL/2R (D) and HCT116R (E). (F) Box plot of log doubling time (DT) estimate of MDA-MB-231
experimental metastasis data. *P b 0.5. R, resistant.
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Metabolic analysis of buffer therapy resistant and sensitive cells. A. Line graph showing sensitive and resistant cells oxygen consumption
rates (OCR) through a mitochondrial stress test. Five basal measurements were obtained while cells were in media containing 5.55 mmol/l
glucose, 2mmol/l glutamine and 1mmol/l pyruvate. Treatment of cellswith oligomycin (1 μmol/l) led to a decrease inOCR that can be related
to ATP production, followed by an increase in OCR to maximal respiration rates after treatment with FCCP (1 μmol/l). Finally, complete
OXPHOS inhibition was achieved after treatment with Rotentone (1 μmol/l) and Antimycin A (1 μmol/l) B. Line graph showing sensitive and
resistant cells extracellular acidification rates (ECAR) through a glycolytic stress test. Five basalmeasurements of cells that had been glucose
starved for 2 hours showsnon-glycolytic acidification. Stimulationof cellswith glucose (5.55mmol/l) results in basal glycolysis levels,which is
increased to maximal glycolysis flux upon treatment with oligomycin (1 μmol/l). Glycolysis inhibition is achieved with treatment of 2DG (100
mmol/l). Data was normalized to mg protein and is reported as mean ± SD. R=Resistant, S=Sensitive.
Supplemental Figure 3.
Metabolic profile analysis of HCT116-Luc and HCT116-GFP cells. Glycolytic and mitochondrial stress tests show different metabolic
profiles of HCT116-Luc and HCT116-GFP cells. (A) Extracellular acidification rates (ECAR) of cells after stimulation of glycolysis with
glucose (5.55 mmol/l), oligomycin (1 μmol/l) and glycolysis inhibitor, 2DG (100 mmol/l). (B) Oxygen consumption rates (OCR) of cells
before treatment with oligomycin (1 μmol/l), FCCP (1 μmol/l) and Rotentone (1 μmol/l) and Antimycin A (1 μmol/l). (C) OCR/ECAR ratio of
cells during basal metabolism. (D) Representative brightfield microscopy images of HCT116-Luc and HCT116-GFP cells in pH 7.4 culture
conditions. Data shown as mean ± SD. Scale bars represent 100 μm.
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Supplemental Figure 4.
Morphologies in a 3D matrix in vitro. LL/2R and PC3MS cells were seeded onto a thick (500-1000 μm) layer of polymerized matrigel and
invaded into the matrix over a period of 72 hours in pH 6.8 or pH 7.4 media. Single cells were imaged using confocal microscopy for
morphological studies. Additional representative images of PC3MS cells (upper panels) and LL/2R cells (lower panels) show a 3D
reconstruction of at least 20 slices. Phalloidin (F-actin) is shown in red; Hoechst nuclear stain is shown in blue. Scale bars represent
10 μm. R, resistant; S, sensitive.
Supplemental Table 1. qPCR primer sequences.
h/m MMP2 FW 5’-AGATCTTCTTCTTCAAGGACCGCTT-3’





h/m MMP9 FW 5’-CGGAGCACGGAGACGGGTATC-3’
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